Dalton Pharma Services and Clarity Pharmaceuticals Enter Into Manufacturing Services Agreement

Dalton Pharma Services and Clarity Pharmaceuticals Enter Into Manufacturing Services Agreement

Dalton Pharma Services, a leading provider of development and manufacturing services to pharmaceutical companies, today announced the Company has entered into a Manufacturing Services Agreement with Clarity Pharmaceuticals based in Sydney, Australia. Clarity is a specialty radiopharmaceutical company dedicated to the development of clinical tools for PET imaging and companion diagnostics.
Dalton Pharma Services will provide cGMP chemistry manufacturing, scale up, aseptic fill/finish services and analytical support for Clarity's PET based companion diagnostics and radio-immunotherapeutics development program.

"Our expert capabilities in the manufacture of complex chemical products, including conjugation under sterile cGMP conditions and our strength in aseptic filling, solidified the manufacturing agreement," said Peter Pekos, CEO of Dalton. "We are excited to have the opportunity to work with Clarity in bringing this breakthrough imaging technology from a research setting to the drug development industry. Adding Clarity to our growing list of strategic relationships with innovative clients is an important milestone for Dalton," Pekos continued.

Dr Matt Harris, Managing Director of Clarity remarked, "The alliance with Dalton is a key part of our ongoing success in making our novel diagnostic tools quickly available to the pharmaceutical development industry. Therapeutic targeting is one of the biggest opportunities for the advancement of novel treatments today. Clarity is pleased to launch this technology for use by the global pharmaceutical community". Clarity benefits tremendously from having the facilities and technical expertise found at Dalton. The opportunity to partner with a company that provides all aspects of manufacturing as well as conjugation and analytical services fits perfectly with Clarity's capital-efficient business model. The high degree of interest in targeted imaging for biopharmaceuticals makes our technology a breakthrough for this growing area of pharmaceutical development."

About Dalton:
Dalton Chemical Laboratories Inc. o/a Dalton Pharma Services, based in Toronto, Canada, supplies chemistry, analytical and formulation development services to the biotechnology and pharmaceutical industries in the areas of chemistry, medicinal chemistry and fine chemical manufacture. It's modern, Health Canada approved facilities offer cGMP manufacturing of sterile aseptic liquids and solid dosage forms to its customers at any stage of the regulatory process (Phase I, II, III or commercial). Dalton conducts sterile fills in vials or syringes, either aseptically or terminally sterilized. Dalton also produces cGMP active pharmaceutical ingredients at the gram or kilogram scale. In addition, Dalton's analytical chemistry laboratory offers method development, validation and ICH stability programs to its clients. Dalton Pharma Services is a privately held company. Further information can be found at http://www.dalton.com.

About Clarity Pharmaceuticals Pty Ltd:
Founded in 2010, Clarity Pharmaceuticals is a private, Sydney-based company. Clarity is focused on developing PET radiopharmaceuticals using technology licensed from the Australian Nuclear Science and Technology Organisation (ANSTO) and the University of Melbourne.

Clarity offers chelators and imaging services to external parties who require PET imaging. Clarity has access to world-class infrastructure and researchers in the field of nuclear medicine. Our niche is the field of theranostics and companion diagnostics. We focus on biological molecules with longer clearance rates than small molecule drugs. Our internal research programs are focused on PET based companion diagnostics and radio-immunotherapeutics in the following disciplines:
1. Oncology
2. Paediatrics
3. Neurology
4. Cardiovascular disease

Suggested Articles

Major CRO player Pharmaceutical Product Development is set to go back on the public markets after announcing its IPO plans.

Dubbed “Project Nightingale,” the efforts were announced amid concerns and federal inquiries into the data’s safekeeping and patient consent for use.

Independent site management organization Panthera Biopartners has kick-started its first clinical trial in the U.K.